Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan

Table 3

Adverse events.

	G1		G2		G3		G4		Total
	𝑛	%	𝑛	%	𝑛	%	𝑛	%	𝑛	%
Leukocytopenia	1	6	1	6	1	6	0	0	3	17
Neutropenia	1	6	1	6	0	0	1	6	3	17
Anemia	2	11	0	0	0	0	0	0	2	11
Infusion reaction	4	22	0	0	0	0	0	0	4	22
Conduction disorder	1	6	0	0	0	0	0	0	1	6
Ventricular arrhythmia	2	11	0	0	0	0	0	0	2	11
Malaise	3	17	0	0	0	0	0	0	3	17
Hypotension	1	6	0	0	0	0	0	0	1	6
Pharyngitis	2	11	1	6	0	0	0	0	3	17
Bronchitis	0	0	1	6	0	0	0	0	1	6
Herpes zoster infection	0	0	1	6	0	0	0	0	1	6
Diarrhea	1	6	1	6	0	0	0	0	2	11
AST increased	3	17	0	0	0	0	0	0	3	17
ALT increased	2	11	0	0	0	0	0	0	2	11
Nausea	1	6	0	0	0	0	0	0	1	6
Palpitations	1	6	0	0	0	0	0	0	1	6
Allergic rhinitis	1	6	0	0	0	0	0	0	1	6
Constipation	1	6	1	6	0	0	0	0	2	11
Insomnia	2	11	0	0	0	0	0	0	2	11
Peripheral neuropathy	2	11	0	0	0	0	0	0	2	11
Creatinine increased	1	6	0	0	0	0	0	0	1	6
Acne	0	0	1	6	0	0	0	0	1	6
Anorexia	1	6	0	0	0	0	0	0	1	6

AST: aspartate aminotransferase; ALT: alanine aminotransferase.